Arthrocare considers future
This article was originally published in The Gray Sheet
Executive Summary
ArthroCare, maker of minimally invasive Coblation devices that use low-temperature radiofrequency energy to gently dissolve soft tissue, said March 3 that its Board of Directors is evaluating financial and strategic alternatives, including recapitalization, stock repurchase, sale of assets or strategic business combinations. The board's decision is based on its belief that ArthroCare's current stock price - which closed March 3 at $43 - does not reflect the fundamental value of the business
You may also be interested in...
ArthroCare Restatement Will Cut Up To $37 Million From ’06-’08 Sales Reports
Radiofrequency surgical instrument maker ArthroCare plans to restate previously filed financial statements from 2006-2008 to account for improper recording of sales to certain entities, resulting in a $26 million-$37 million reduction in previously recorded revenues
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.